Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma Recurrent

Interventions: Drug: Temozolomide
Drug: Dasatinib
Drug: Irinotecan
Drug: Rapamycin

First Posted Date: 2011-11-09

Last Posted Date: 2020-10-06

Lead Sponsor: University of Regensburg

Target Recruit Count: 130

Registration Number: NCT01467986

Locations: 🇩🇪
University Hospital Regensburg, Department of Pediatric Hematology and Oncology, Regensburg, Germany

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Phase 1

Completed

Conditions: Colorectal Cancer
Squamous Cell Head and Neck Cancer
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Other Tumors With EGFR Dependence

Interventions: Drug: MM-121
Drug: Cetuximab
Drug: Irinotecan

First Posted Date: 2011-10-13

Last Posted Date: 2016-09-08

Lead Sponsor: Merrimack Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT01451632

Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Folinic Acid
Drug: Oxaliplatin
Drug: 5-FU
Drug: Irinotecan
Drug: Bevacizumab
Drug: Cetuximab

First Posted Date: 2011-09-29

Last Posted Date: 2021-06-18

Lead Sponsor: UNICANCER

Target Recruit Count: 256

Registration Number: NCT01442935

Locations: 🇫🇷
Centre Val d'Aurelle, Montpellier, France

Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Oxaliplatin
Drug: Folinic Acid
Drug: 5-fluoro-uracil
Drug: Irinotecan
Drug: Bevacizumab
Drug: Cetuximab

First Posted Date: 2011-09-28

Last Posted Date: 2022-01-11

Lead Sponsor: UNICANCER

Target Recruit Count: 133

Registration Number: NCT01442649

Locations: 🇫🇷
Centre rené Gauducheau, Saint-herblain, France

FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Phase 1

Completed

Conditions: Pancreatic Neoplasms

Interventions: Drug: Oxaliplatin
Drug: Irinotecan
Drug: Leucovorin
Drug: Fluorouracil
Other: laboratory biomarker analysis
Other: flow cytometry
Other: immunohistochemistry staining method
Other: pharmacological study
Drug: PF-04136309

First Posted Date: 2011-08-09

Last Posted Date: 2016-09-19

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 44

Registration Number: NCT01413022

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Phase 1

Completed

Conditions: Colorectal Carcinoma
CRC

Interventions: Biological: JX-594
Drug: Irinotecan

First Posted Date: 2011-07-15

Last Posted Date: 2021-01-08

Lead Sponsor: Jennerex Biotherapeutics

Target Recruit Count: 52

Registration Number: NCT01394939

Locations: 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇫🇷
Hôpital Saint Antoine, Paris, France

and more 8 locations

Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Recurrent Rectal Carcinoma
Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer
Recurrent Colon Carcinoma

Interventions: Biological: Bevacizumab
Drug: Fluorouracil
Drug: Irinotecan Hydrochloride
Drug: Leucovorin Calcium
Drug: Sorafenib Tosylate

First Posted Date: 2011-06-28

Last Posted Date: 2017-04-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT01383343

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States